KHẢO SÁT ĐỘ NGƯNG TẬP TIỂU CẦU Ở NGƯỜI BỆNH ĐỘNG MẠCH VÀNH ĐƯỢC ĐIỀU TRỊ BẰNG ASPIRIN VÀ/ HOẶC CLOPIDOGREL

Thắng Trần Văn Công; Hoàng Tạ Anh; Cẩm Trương Đình

doi:10.59354/ydth175.2023.251

Keywords:

Platelet aggregation, coronary artery disease, drug resistance

Abstract

Objective: Evaluation of platelet aggregation and antiplatelet drug resistance rate in patients with coronary artery disease patients who were treated by aspirin and/ or clopidogrel.

Method: A cross – sectional study was conducted on 201 coronary artery disease (CAD) patients who were treated by aspirin and/ or clopidogrel, with a minimum stable medication duration of 7 days. Platelet aggregation was measured by Light Transmission Aggregometry. Criteria for determining resistance to antiplatelet drugs were based on the 2010 HTPR (high on-treatment platelet reactivity) of American College of Cardiology (ACC) consensus.

Results: 150 men and 50 women, average age is 62,83 ± 11,02, Median/ interquartile range (Med/IQR) of platelet aggregation when using aspirin is 7,0 /14,5 and clopidogrel is 51,45 /20,9. The rate of aspirin resistance was 19,05%, clopidogrel resistance was 61,11%, and resistance to both drugs was 13,44%. No significant relationship was found between platelet aggregation and age, gender and body mass index (BMI) (p > 0,05).

Conclusion: The resistance rate to clopidogrel in the treatment of coronary artery disease is quite high (up to 61,11%). Dual antiplatelet combination therapy (asprin and clopidogrel) increases treatment effectiveness and reduces the rate of antiplatelet resistance.

References

Cassar A, Holmes DR Jr, Rihal CS et al. (2009). Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc, 84(12):1130-46.

Gum PA, Kottke-Marchant K, Welsh PA et al. (2003). A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 41: 961-965.

Lê Tùng Lam (2012). Nghiên cứu độ ngưng tập tiểu cầu ở bệnh nhân trước và sau can thiệp đặt stent động mạch vành. Luận văn Thạc sỹ y học. Trường đại học Y Hà Nội.

Bonello L, Tantry US, Marcucci R et al. (2010). Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol, 56(12):919-33.

René M’Pembele, Samantha Ahlbrecht, Carolin Helten et al. (2023), High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel, Pharmacology (2023) 108 (1): 83–89.

Mega JL, Close SL, Wiviott SD et al. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med, 360(4):354-62.

Vũ Hồng Điệp (2000). Một số nhận xét về độ ngưng tập tiểu cầu ở người cao tuổi bình thường. Tạp chí Y học thực hành, 2:36-37.

Breet NJ, Sluman MA, van Berkel MA et al. (2011). Effect of gender difference on platelet reactivity. Neth Heart J., 19(11):451-457.

Sibbing D, von Beckerath O, Schömig A et al. (2007). Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol, 100(2):203-5.